← FDA DRUG APPROVALS

FDA ANDA · ANDA078776

ONDANSETRON

ondansetron hydrochloride

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA078776
TYPE
ANDA
ORIGINAL APPROVAL
2007-11-28
LATEST ACTION
2025-10-23
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ONDANSETRON HYDROCHLORIDEPrescription
ONDANSETRON HYDROCHLORIDE EQ 4MG BASE/5ML · SOLUTION · ORAL

Approval history

2025-10-23Labeling · Supplement 19 · standardAP
2022-06-23Labeling · Supplement 15 · standardAP
2022-06-23Labeling · Supplement 14 · standardAP
2018-03-07Labeling · Supplement 10 · standardAP
2017-03-27Labeling · Supplement 9 · standardAP
2014-12-08Labeling · Supplement 7 · standardAP
2014-12-08Labeling · Supplement 5 · standardAP
2011-10-13Labeling · Supplement 2AP
2011-01-20Labeling · Supplement 1AP
2007-11-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →